Metoprolol
Other / unclassified targets ADRB1 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 7 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (3) | US (FDA) | TOPROL-XL | — | 2001-02-05 – 2007-07-18 | fda.gov ↗ |
| Label expansions (3) | US (FDA) | LOPRESSOR | — | 1983-04-12 – 1986-06-27 | fda.gov ↗ |
| Approved | US (FDA) | LOPRESSOR | — | 1978-08-07 | fda.gov ↗ |
Trials 134 · started per year
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 03 trials | ||||||
| Phase 0 | NCT05891119 | Jun 2023 → Aug 2024 | atopic eczema | Amgen | Completed | No outcome recorded |
| Phase 0 | NCT05096884 | Mar 2022 → Sep 2023 | COVID-19, cardiac rhythm disease | Hackensack Meridian Health | Terminated | No outcome recorded Stop: Enrollment |
| Phase 0 | NCT02025348 | Jan → Mar 2014 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 132 trials | ||||||
| Phase 1 | NCT06808802 | Feb → Apr 2025 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT06686628 | Nov 2024 → Nov 2025 | atopic eczema | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT05745337 | Feb → Dec 2023 | atrial fibrillation, diastolic heart failure | University of Vermont | Unknown | No outcome recorded |
| Phase 1 | NCT07823140 | Aug 2022 → Apr 2023 | — | Chinese University of Hong Kong | Completed | No outcome recorded |
| Phase 1 | NCT04425902 | Dec 2020 → Mar 2021 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Phase 1 | NCT04504045 | Sep 2020 → May 2022 | type 2 diabetes mellitus | University of Southern Denmark | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT04254783 | May 2020 → Oct 2022 | Crohn disease, ulcerative colitis | AbbVie | Completed | No outcome recorded |
| Phase 1 | NCT03556592 | Aug 2018 → Mar 2020 | atopic eczema | LEO Pharma | Completed | No outcome recorded |
| Phase 1 | NCT03488719 | Jul 2018 → Jun 2019 | — | Saniona | Completed | No outcome recorded |
| Phase 1 | NCT03457597 | Mar → Apr 2018 | — | Corcept Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT03441412 | Feb → Mar 2018 | — | Vastra Gotaland Region | Completed | No outcome recorded |
| Phase 1 | NCT03286829 | Dec 2017 → Feb 2018 | — | Saniona | Completed | No outcome recorded |
| Phase 1 | NCT03103568 | Mar → Jun 2017 | — | Swedish Orphan Biovitrum | Completed | No outcome recorded |
| Phase 1 | NCT02940379 | Oct → Dec 2016 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT02772601 | Sep 2016 → Jun 2017 | psoriasis | AbbVie | Completed | No outcome recorded |
| Phase 1 | NCT02647086 | Dec 2015 → Jul 2016 | atopic eczema | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT02578277 | Nov → Dec 2015 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Phase 1 | NCT02361619 | Feb 2015 → Sep 2016 | — | Turku University Hospital | Completed | No outcome recorded |
| Phase 1 | NCT02254148 | Oct → Dec 2014 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02045966 | Feb → Apr 2014 | hepatitis C virus infection | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT02097511 | Dec 2013 → Jan 2014 | hypertensive disorder, peripheral arterial disease | Ajou University School of Medicine | Completed | No outcome recorded |
| Phase 1 | NCT01902550 | Jul → Oct 2013 | — | Janssen Research & Development, LLC | Withdrawn | No outcome recorded |
| Phase 1 | NCT01585623 | Jun 2012 → Mar 2013 | cancer | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT01659944 | May → Jun 2012 | — | Genzyme, a Sanofi Company | Completed | No outcome recorded |
| Phase 1 | NCT01386593 | May 2011 → Jan 2012 | — | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 1 | NCT01324388 | Mar → Aug 2011 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01211821 | Sep → Nov 2010 | atrial fibrillation | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT01845194 | Dec 2009 → Oct 2013 | mitochondrial membrane transport disorder | Institute of Application-oriented Research and Clinical Trials GmbH | Completed | No outcome recorded |
| Phase 1 | NCT00700947 | Oct 2007 → Jun 2009 | mitral valve insufficiency | Wake Forest University Health Sciences | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT00648271 | Dec 2002 | — | Mylan Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1 | NCT01478490 | Sep → Nov 2002 | — | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 1 | NCT00223717 | Jan 2001 → Jan 2017 | hypertensive disorder | Vanderbilt University | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT04082910 | Sep 2019 → Dec 2022 | cancer, hematopoietic and lymphoid cell neoplasm | Chinese PLA General Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT03361280 | Feb 2015 → Mar 2016 | chronic kidney disease | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Completed | No outcome recorded |
| Phase 215 trials · 2 met primary · 2 missed | ||||||
| Phase 2 | NCT07511894 | May 2026 → Dec 2027 expected | gastric cancer | Nanfang Hospital, Southern Medical University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT04977180 | Mar 2022 → Mar 2028 expected | acute myeloid leukemia | University of Virginia | Recruiting | No outcome recorded |
| Phase 2 | NCT05198362 | Dec 2021 → Dec 2022 | Prader-Willi syndrome | Saniona | Withdrawn | No outcome recorded Stop: Business |
| Phase 2 | NCT04562116 | Dec 2021 → Jun 2023 | atopic eczema | Galderma R&D | Completed | No outcome recorded |
| Phase 2 | NCT04633005 | Nov 2021 → Oct 2025 | heart failure | University of Texas Southwestern Medical Center | Completed | Met primary |
| Phase 2 | NCT05147415 | Nov 2021 → Dec 2022 | acquired hypothalamic obesity | Saniona | Withdrawn | No outcome recorded Stop: Business |
| Phase 2 | NCT03845075 | Feb 2019 → Oct 2020 | acquired hypothalamic obesity | Saniona | Completed | No outcome recorded |
| Phase 2 | NCT03696758 | Oct 2018 → Feb 2020 | pulmonary immaturity | University of Wisconsin, Madison | Completed | No outcome recorded |
| Phase 2 | NCT03070184 | Apr 2017 → Dec 2023 | hypertensive disorder | University of Alabama at Birmingham | Completed | No outcome recorded |
| Phase 2 | NCT03149445 | Mar 2017 → Jul 2019 | Prader-Willi syndrome | Saniona | Completed | Missed primary |
| Phase 2 | NCT02737891 | Apr 2016 → Jan 2017 | type 2 diabetes mellitus | Saniona | Completed | Met primary |
| Phase 2 | NCT01434134 | Sep 2011 → Sep 2014 | breast cancer, heart failure | University Hospital, Akershus | Completed | Missed primary |
| Phase 2 | NCT03882710 | Jan 2010 → Oct 2012 | diastolic heart failure | Post Graduate Institute of Medical Education and Research, Chandigarh | Completed | No outcome recorded |
| Phase 2 | NCT00302692 | Dec 2005 → Sep 2008 | cardiovascular disorder | University of Texas Southwestern Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT00000499 | Sep 1980 → May 1983 | heart disorder, hypertensive disorder | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT07268170 | Dec 2025 → Sep 2028 expected | coronary artery disorder, ischemic disease | Gødstrup Hospital | Enrolling by invitation | No outcome recorded |
| Phase 2/3 | NCT02408172 | Oct 2013 → Jun 2017 | hypertensive disorder, obstructive sleep apnea syndrome | First Affiliated Hospital of Harbin Medical University | Unknown | No outcome recorded |
| Phase 313 trials · 1 met primary | ||||||
| Phase 3 | NCT05631730 | Jan 2023 → Jun 2026 overdue | cardiac rhythm disease, mitral valve prolapse | Oslo University Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT05066633 | Aug 2021 → Jun 2023 | Duchenne muscular dystrophy | Medical University of Gdansk | Unknown | No outcome recorded |
| Phase 3 | NCT04980716 | Jun 2021 → Jan 2026 overdue | non-small cell lung carcinoma | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 3 | NCT03541109 | May 2019 → Aug 2023 | ST-elevation myocardial infarction | Isfahan University of Medical Sciences | Unknown | No outcome recorded |
| Phase 3 | NCT02269696 | Mar 2018 | breast cancer | Kuopio University Hospital | Withdrawn | No outcome recorded |
| Phase 3 | NCT03138603 | Dec 2016 → Apr 2023 | heart disorder | University of Chicago | Completed | No outcome recorded |
| Phase 3 | NCT00077948 | Jul 2003 → Jun 2005 | congestive heart failure | Gilead Sciences | Terminated | No outcome recorded |
| Phase 3 | NCT00642096 | Jun 2003 → Jul 2004 | essential hypertension | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00182039 | Oct 2002 → Jul 2007 | cardiovascular disorder | Hamilton Health Sciences Corporation | Terminated | Met primary |
| Phase 3 | NCT00255502 | Jul 2002 → ? | hypertensive disorder | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00255528 | Jul 2002 → ? | hypertensive disorder | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00038077 | Aug 2001 → Sep 2003 | congestive heart failure | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT04364139 | Feb 1995 → Sep 2001 | chronic kidney disease, nephrosclerosis | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | Mixed |
| Phase 444 trials · 3 met primary · 3 missed | ||||||
| Phase 4 | NCT07490067 | Oct 2026 → Jul 2029 expected | symptomatic heart failure | University of Michigan | Recruiting | No outcome recorded |
| Phase 4 | NCT07597564 | Jun 2026 → May 2027 expected | — | Fujian Provincial Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07240909 | Jan → Dec 2026 expected | hypertensive disorder | The Third Xiangya Hospital of Central South University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06825728 | Feb 2025 → Feb 2028 expected | chronic obstructive pulmonary disease, systolic heart failure | Xiangya Hospital of Central South University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06569212 | Sep 2024 → Sep 2026 overdue | subarachnoid hemorrhage | Madeleine Puissant | Recruiting | No outcome recorded |
| Phase 4 | NCT06035978 | Mar 2024 → Apr 2026 | symptomatic heart failure | University Hospital Ostrava | Unknown | No outcome recorded |
| Phase 4 | NCT06357104 | Feb → Mar 2024 | — | Pachankis, Yang I., M.D. | Completed | No outcome recorded |
| Phase 4 | NCT05585125 | Feb 2024 → Jul 2026 overdue | diastolic heart failure | Weill Medical College of Cornell University | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT05019027 | Jan 2024 → Mar 2026 overdue | amyloidosis, heart disorder | Weill Medical College of Cornell University | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT05711810 | Jan 2023 | Orthocoronavirinae infectious disease, myocarditis | Yang I. Pachankis | Completed | No outcome recorded |
| Phase 4 | NCT05637853 | Oct 2022 → Aug 2024 overdue | symptomatic heart failure | Göteborg University | Active not recruiting | No outcome recorded |
| Phase 4 | NCT05377203 | Jul 2022 → Jul 2023 | hypertensive disorder | The Third Xiangya Hospital of Central South University | Completed | Met primary |
| Phase 4 | NCT04234477 | Dec 2021 → Jun 2022 | atrial fibrillation | Boston University | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT04133532 | Mar 2020 → Feb 2023 | hypertrophic cardiomyopathy | University Hospital, Motol | Completed | No outcome recorded |
| Phase 4 | NCT03778554 | Dec 2018 → Apr 2025 overdue | ST-elevation myocardial infarction | Bispebjerg Hospital | Active not recruiting | Met primary |
| Phase 4 | NCT03596385 | Oct 2018 → Jan 2025 | myocardial infarction | National Center for Cardiovascular Research Carlos III | Completed | Missed primary |
| Phase 4 | NCT03278509 | Sep 2017 → Nov 2023 | ST-elevation myocardial infarction | Karolinska Institutet | Unknown | Missed primary |
| Phase 4 | NCT03008382 | Mar 2017 → Mar 2022 | interstitial cystitis, myofascial pain syndrome | Virginia Commonwealth University | Completed | No outcome recorded |
| Phase 4 | NCT02251509 | Dec 2016 → Sep 2017 | atrial fibrillation | Creighton University | Unknown | No outcome recorded |
| Phase 4 | NCT02924454 | Sep 2016 → Mar 2017 | hypertensive disorder | Mikkel Bring Christensen | Completed | No outcome recorded |
| Phase 4 | NCT02746575 | Nov 2015 → Oct 2016 | intrinsic cardiomyopathy | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 4 | NCT01755663 | Dec 2014 | coronary artery disorder | Col. Suthee Panichkul | Unknown | No outcome recorded |
| Phase 4 | NCT05008250 | Jan 2014 → Aug 2015 | cardiac rhythm disease | Xuanwu Hospital, Beijing | Completed | No outcome recorded |
| Phase 4 | NCT02025465 | Dec 2013 → Feb 2023 | atrial fibrillation, atrial flutter | CAMC Health System | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT01605370 | Jun 2012 → Mar 2013 | hypertensive disorder | Mayo Clinic | Terminated | No outcome recorded |
| Phase 4 | NCT01595516 | Feb 2012 → Oct 2017 | hypertensive disorder | University of Colorado, Boulder | Completed | No outcome recorded |
| Phase 4 | NCT01655303 | Feb → Dec 2011 | atrial fibrillation | Tehran University of Medical Sciences | Completed | No outcome recorded |
| Phase 4 | NCT00992056 | Dec 2010 → Feb 2012 | hypertensive disorder | University of Miami | Completed | No outcome recorded |
| Phase 4 | NCT01213173 | Oct 2010 → Sep 2011 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT01203852 | Aug 2010 → Apr 2014 | hypertensive disorder | University of Florida | Completed | No outcome recorded |
| Phase 4 | NCT00999102 | Oct 2009 → Jan 2011 | hypertensive disorder | Weill Medical College of Cornell University | Completed | Missed primary |
| Phase 4 | NCT00819104 | Nov 2008 → Aug 2009 | essential hypertension | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT01029223 | Oct 2008 → Dec 2011 | hypertensive disorder | Bayside Health | Withdrawn | No outcome recorded |
| Phase 4 | NCT00885651 | Sep 2008 → Aug 2009 | heart failure | Rigshospitalet, Denmark | Unknown | No outcome recorded |
| Phase 4 | NCT00491387 | Aug 2007 → Jan 2009 | hypertensive disorder | University of Cincinnati | Terminated | No outcome recorded |
| Phase 4 | NCT00241904 | May 2006 → May 2010 | atherosclerosis, coronary artery disorder, diabetes mellitus, hypertensive disorder +1 | Johns Hopkins University | Completed | Mixed |
| Phase 4 | NCT00288548 | Feb 2006 → ? | chronic obstructive pulmonary disease | Martini Hospital Groningen | Unknown | No outcome recorded |
| Phase 4 | NCT00861016 | Oct 2005 → Apr 2006 | essential hypertension | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT01917149 | Mar 2005 → Jul 2013 | dilated cardiomyopathy | Xijing Hospital | Completed | Met primary |
| Phase 4 | NCT00166400 | Jul 2004 → Jul 2007 | heart valve disorder | Mayo Clinic | Completed | No outcome recorded |
| Phase 4 | NCT00497003 | Feb 2004 → Oct 2007 | — | Bispebjerg Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00060931 | Jun 2001 → Apr 2004 | hypertensive disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT00060918 | Jun 2001 → Apr 2004 | hypertensive disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT00222573 | Jul 1999 → Feb 2005 | acute myocardial infarction | University of Oxford | Completed | Mixed |
| Phase not applicable23 trials · 1 met primary | ||||||
| — | NCT07519161 | Apr 2026 → Dec 2029 expected | atrial fibrillation | Shanghai East Hospital | Not yet recruiting | No outcome recorded |
| — | NCT07099677 | Aug 2025 → Jun 2026 overdue | essential hypertension | Abant Izzet Baysal University | Recruiting | No outcome recorded |
| — | NCT07568873 | Jan → Dec 2024 | — | Zagazig University | Completed | No outcome recorded |
| — | NCT05741385 | Oct 2023 → Aug 2024 | cirrhosis of liver | Boehringer Ingelheim | Completed | No outcome recorded |
| — | NCT07074834 | Feb 2021 → Sep 2022 | coronary artery disorder | Shiyan City Renmin Hospital | Completed | No outcome recorded |
| — | NCT04513509 | Oct 2020 → Jun 2022 | atrial fibrillation | National Taiwan University Hospital | Completed | No outcome recorded |
| — | NCT04221919 | Jan 2020 → Jan 2021 | strictly posterior acute myocardial infarction | Qilu Hospital of Shandong University | Unknown | No outcome recorded |
| — | NCT03337945 | Apr 2018 → Jun 2021 | cirrhosis of liver | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| — | NCT03413410 | Feb 2018 → Jul 2019 | acute coronary syndrome | Yun Dai Chen | Unknown | No outcome recorded |
| — | NCT03579914 | Nov 2017 → Aug 2020 | heart failure, myocardial infarction | Harbin Medical University | Completed | No outcome recorded |
| — | NCT02248753 | Oct 2014 → Nov 2018 | atrial fibrillation | Maastricht University Medical Center | Completed | Met primary |
| — | NCT02293096 | Sep 2014 → Aug 2017 | hypertensive disorder | University of Colorado, Denver | Terminated | No outcome recorded Stop: Business |
| — | NCT01658657 | Oct 2012 → Jul 2014 | hypertensive disorder, proteolytic capacity of plasma | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
| — | NCT01544959 | Jan 2010 → Jan 2013 | breast cancer | University of Sherbrooke | Completed | No outcome recorded |
| — | NCT01051947 | Dec 2009 → May 2010 | — | Creighton University | Withdrawn | No outcome recorded |
| — | NCT00995072 | Oct 2009 → Apr 2013 | hypertensive disorder, sexual disorder | East Coast Institute for Research | Completed | No outcome recorded |
| — | NCT00849810 | Jan 2009 → Nov 2010 | hypertensive disorder | University of Mississippi Medical Center | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT00627861 | Nov 2008 → May 2010 | hypertensive disorder | The Rogosin Institute | Terminated | No outcome recorded |
| — | NCT00756236 | Oct 2008 → Sep 2015 | myocardial ischemia | University of Oklahoma | Completed | No outcome recorded |
| — | NCT00578617 | Sep 2006 → Feb 2009 | atrial fibrillation | Mayo Clinic | Completed | No outcome recorded |
| — | NCT00214318 | Jan 2005 → Feb 2007 | heart failure | University of Wisconsin, Madison | Completed | No outcome recorded |
| — | NCT00198614 | Jan 2005 → ? | atrial fibrillation, coronary artery disorder | Ministry of Health, Labour and Welfare, Japan | Completed | No outcome recorded |
| — | NCT00475462 | Jul 2001 → Dec 2003 | syncope, familial vasovagal | Peking University First Hospital | Completed | No outcome recorded |
| Comparator or background therapy133 trials | ||||||
| Phase 0 | NCT02029118 Background | Oct 2012 → May 2015 | — | Chengdu University of Traditional Chinese Medicine | Completed | Met primary |
| Phase 1 | NCT01523002 Comparator | Jan → Jul 2012 | malaria | Medicines for Malaria Venture | Completed | No outcome recorded |
| Phase 1 | NCT01337674 Background | Apr → Nov 2011 | hypertensive disorder | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT01187862 Background | Jul 2010 → Feb 2011 | — | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 1 | NCT02264002 Comparator | Feb → Nov 2003 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Show all 133 trials opens the full record — a long page | ||||||
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2023-08-16 | Lupin Limited | Regulatory Lupin Receives Approval from U.S. FDA for Metoprolol Succinate Extended-Release Tablets USP lupin.com ↗ |
| 2023-04-20 | Zydus Lifesciences Limited | Regulatory Zydus receives final approval from the USFDA for Metoprolol Tartrate Tablets USP, 25 mg, 50 mg, and 100 mg zyduslife.com ↗
Zydus receives final approval from the USFDA for Metoprolol Tartrate Tablets USP, 25 mg, 50 mg, and 100 mg |
| 2015-09-21 | Saniona | Results Provides update on Tesomet and AN363 saniona.com ↗
Metoprolol blunts the increase in heart rate caused by Tesofensine in volunteers in a Phase 1 study. |
All press releases naming this drug 6 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-08-16 | Lupin Limited | Lupin Receives Approval from U.S. FDA for Metoprolol Succinate Extended-Release Tablets USP lupin.com ↗ |
| 2023-04-20 | Zydus Lifesciences Limited | Zydus receives final approval from the USFDA for Metoprolol Tartrate Tablets USP, 25 mg, 50 mg, and 100 mg zyduslife.com ↗ |
| 2017-11-29 | Lannett Company, Inc. | Lannett Announces Agreement For Authorized Generic Version Of Toprol-XL® investorroom.com ↗ |
| 2016-10-04 | AstraZeneca | AstraZeneca enters agreement with Aralez for beta-blocker medicine Toprol-XL in the US astrazeneca.com ↗ |
| 2016-02-24 | Saniona | Has obtained patent in the United States until 2033 for the combination of tesofensine and Metoprolol saniona.com ↗ |
| 2015-09-21 | Saniona | Provides update on Tesomet and AN363 saniona.com ↗ |
Evidence & citations 26 cited values
Every value below carries the sentence it was read from. 270 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Metoprolol | “We administered the Basel phenotyping cocktail (caffeine, efavirenz, flurbiprofen, omeprazole, metoprolol, midazolam) to patients with liver cirrhosis (n = 16 Child A, n = 15...” PMID 37328712 ↗ Jun 2023205“Intervention of conventional therapy group: controlling blood pressure using amlodipine, valsartan, metoprolol and terazosin and so on , protecting the renal function using...” NCT02966717 ↗ “The first hypothesis of the study is that substituting fentanyl by esmolol and metoprolol during general anesthesia for patients undergoing mastectomy will result in less pain...” NCT01544959 ↗ “1 mg tesofensine (2 tablets of 0.5 mg), 25 mg commercial IR metoprolol (1 tablet of 25 mg), 75 mg commercial ER metoprolol (1 tablet of 25 mg ER metoprolol and 1 tablet of 50...” NCT03286829 ↗ “Other names: acebutolol, atenolol, betaxolol, bisoprolol, carvedilol, labetalol, metoprolol, metoprolol succinate, metoprolol tartrate, nadolol, nebivolol, propranolol,...” NCT05585125 ↗ “Effects of BMS-955176 on the Single-dose Pharmacokinetics of Probe Substrates (Caffeine, Metoprolol, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin)...” NCT02578277 ↗ “a beta- blocker (metoprolol), in pill form based upon blood pressure and heart rate, may be administered to some subjects to improve the heart's ability to relax and slow the...” NCT03504956 ↗ “A non-selective betablocker: Propranolol Retard 80 mg daily or Nadolol 40 mg daily OR 2) A selective betablocker: Atenolol 25 mg daily, Bisoprolol 2.5 mg daily or Metoprolol 50 mg.” NCT07405229 ↗ “amlodipine 2.5 to 10 mg once daily nifedipine retard 20mg to 40mg twice daily indapamide 2.5mg once daily metoprolol 25mg to 100mg daily methyldopa 125 mg to 500mg twice daily” NCT01500590 ↗ “Single oral dose of a cocktail comprising caffeine (CYP1A2), efavirenz (CYP2B6), losartan (CYP2C9), omeprazole (CYP2C19), metoprolol (CYP2D6), and midazolam (CYP3A4).” NCT07823140 ↗ “probe drugs for simultaneous phenotyping of CYP1A2 (caffeine), CYP2B6 (efavirenz), CYP2C9 (losartan), 2C19 (omeprazole), CYP2D6 (metoprolol), and CYP3A4 (midazolam)” PMID 26123704 ↗ Jan 2016 |
| Known as | Beloc | “Beloc® (Metoprolol) Zok 50 mg and 100 mg Controlled Release Film Tablets” NCT04457323 ↗ |
| Known as | betaloc | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04744571 ↗ |
| Known as | Betaloc ZOK | “An Open-Label, Non-Comparative, Multi-Centre Study to Evaluate the Efficacy and Safety of Metoprolol Succinate Prolonged-Release Tablet (Betaloc Zok) in Patients With Mild to...” NCT00861016 ↗3“Metoprolol (Betaloc ZOK) tablet will be administered orally to patients according to their clinical condition and the decision of the attending physician.” NCT06035978 ↗ “Name: Metoprolol Succinate Extended-Release Tablets (Brand Name: Betaloc® ZOK)” NCT07511894 ↗ “metoprolol succinate prolonged-release tablet (Betaloc ZOK) 47.5mg” NCT02336607 ↗ |
| Known as | ER metoprolol | “OBJECTIVE: To evaluate the efficacy, tolerability, and blood pressure (BP) lowering effect of extended release metoprolol succinate (ER metoprolol) in children 6 to 16 years of...” PMID 17236889 ↗ Feb 2007 |
| Known as | extended-release metoprolol succinate | “we randomly assigned 8351 patients with, or at risk of, atherosclerotic disease who were undergoing non-cardiac surgery to receive extended-release metoprolol succinate...” PMID 18479744 ↗ May 2008 |
| Known as | Lopressor | “Metoprolol- Lopressor” NCT01523054 ↗ |
| Known as | MET | “Drug: Metoprolol (MET)” NCT06967194 ↗ |
| Known as | metoprolol (Toprol XL) | “metoprolol (Toprol XL)” NCT00000620 ↗ |
| Known as | metoprolol CR | “oral metoprolol CR or matching placebo 100 mg” NCT00182039 ↗ |
| Known as | metoprolol CR/XL | “This was a 4-week, multicenter, double-blind, placebo-controlled, randomized, parallel-group study to determine the antihypertensive dose range, efficacy, safety and...” NCT00255528 ↗1“A Safety, Tolerability and Pharmacokinetics Study of TOPROL-XL® (Metoprolol Succinate) Extended-release Tablets (Metoprolol CR/XL) in Hypertensive Pediatric Subjects: A...” NCT00255502 ↗ |
| Known as | metoprolol IR | “The purpose of this study is to evaluate effect of co-administration of JNJ-54452840 and metoprolol tartrate immediate-release (metoprolol IR) compared to metoprolol IR alone...” NCT01902550 ↗ |
| Known as | Metoprolol is lopressor | “Metoprolol is lopressor” NCT00849810 ↗ |
| Known as | metoprolol succinate | “Standard medical therapy for heart failure, including spironolactone (20 mg once daily), metoprolol succinate (25 mg twice daily), and sacubitril/valsartan (50 mg twice daily)....” NCT07130175 ↗53“we randomly assigned 8351 patients with, or at risk of, atherosclerotic disease who were undergoing non-cardiac surgery to receive extended-release metoprolol succinate...” PMID 18479744 ↗ May 2008 “Treatment with the beta-blocker metoprolol succinate in patients with asymptomatic moderate to severe AS has beneficial effects on LV myocardial oxidative metabolism,...” NCT02076711 ↗ “The beta blocker metoprolol succinate will be initiated at a starting low dose of 25 mg daily for two weeks and will be escalated if well tolerated every 2 weeks to a maximum...” NCT05096884 ↗ “Other Names: * acebutolol * atenolol * betaxolol * bisoprolol * carvedilol * labetalol * metoprolol succinate * metoprolol tartrate * nadolol * nebivolol * penbutolol *...” NCT05019027 ↗ “In a double-blind, randomized, crossover study, 19 AA hypertensive patients were randomized to a 12-week treatment period with either nebivolol 10 mg or metoprolol succinate...” PMID 26285691 ↗ Aug 2015 “Patients randomized to beta-blockade will be prescribed oral beta-blocker (metoprolol succinate or bisoprolol) at a dose according to the treating physician.” NCT03278509 ↗ “Subjects will receive metoprolol succinate (Betaloc SR) at a dose of 47.5 mg once daily orally as SR tablets for a period of 4 weeks.” NCT01508325 ↗ “The beta-blocker agent may include atenolol, bisoprolol, carvedilol, metoprolol succinate, or metoprolol tartrate.” NCT07298993 ↗ “Generic drug and accepted dosages will be: * Metoprolol succinate up to a total dose of 200mg daily” NCT03646357 ↗ “evidence-based beta-blockers (extended-release metoprolol succinate, bisoprolol, carvedilol)” NCT07238452 ↗ |
| Known as | Metoprolol Succinate Extended-Release Tablets | “Drug: Metoprolol Succinate Extended-Release Tablets” NCT07378228 ↗ |
| Known as | Metoprolol Sustained-Release Tablets | “High cardiac output type: Metoprolol Sustained-Release Tablets 47.5mg, once daily, orally.” NCT07240909 ↗ |
| Known as | metoprolol tartrate | “The purpose of this study is to evaluate effect of co-administration of JNJ-54452840 and metoprolol tartrate immediate-release (metoprolol IR) compared to metoprolol IR alone...” NCT01902550 ↗23“CYP substrates (Caffeine, Warfarin Sodium, Midazolam, Omeprazole, and Metoprolol Tartrate) will administered orally at Week 0 (Day 1) and Week 10 as per the commercially...” NCT04562116 ↗ “Other Names: * acebutolol * atenolol * betaxolol * bisoprolol * carvedilol * labetalol * metoprolol succinate * metoprolol tartrate * nadolol * nebivolol * penbutolol *...” NCT05019027 ↗ “The beta-blocker agent may include atenolol, bisoprolol, carvedilol, metoprolol succinate, or metoprolol tartrate.” NCT07298993 ↗ “Participants will be administered IV Metoprolol tartrate 15 mg (3 ampoules of 5 ml) diluted in 100 ml of saline.” NCT05847517 ↗ “Metoprolol tartrate will be provided to each patient randomized to the metoprolol group.” NCT00806390 ↗ “A 50 mg tablet of metoprolol tartrate is given as single oral dose 2 weeks apart.” NCT03103568 ↗ “Metoprolol tartrate, target dose: 150 mg daily” NCT04221919 ↗ “metoprolol tartrate 50 mg single oral dose” NCT01044693 ↗ “Intravenous metoprolol tartrate” NCT06592547 ↗ “Drug: Metoprolol tartrate” NCT07706075 ↗ |
| Known as | Metoprolol tartrate immediate-release | “The purpose of this study is to evaluate effect of co-administration of JNJ-54452840 and metoprolol tartrate immediate-release (metoprolol IR) compared to metoprolol IR alone...” NCT01902550 ↗ |
| Known as | metoprolol tartrate IR | “Any potential interaction between JNJ-54452840 and metoprolol tartrate IR will primarily be evaluated by measuring exercise induced heart rate (that is, post exercise).” NCT01902550 ↗ |
| Known as | Metoprolol XL | “Ten weeks after titration subjects will cross over to Metoprolol XL 50mg and titrate to Metoprolol XL 100mg two weeks after cross over.” NCT01049009 ↗ |
| Known as | Selo-Zok | “Drug: Metoprolole (Selo-Zok ®)” NCT00885651 ↗ |
| Known as | Toprol XL | “This was a 4-week, multicenter, double-blind, placebo-controlled, randomized, parallel-group study to determine the antihypertensive dose range, efficacy, safety and...” NCT00255528 ↗7“A Safety, Tolerability and Pharmacokinetics Study of TOPROL-XL® (Metoprolol Succinate) Extended-release Tablets (Metoprolol CR/XL) in Hypertensive Pediatric Subjects: A...” NCT00255502 ↗ “The three antihypertensive drug regimens contained either a calcium channel blocker (amlodipine), β-blocker (metoprolol; Toprol XL), or angiotensin-converting enzyme inhibitor...” NCT04364139 ↗ “whether Toprol xl, a beta-blocker will benefit asymptomatic patients with chronic primary mitral regurgitation” NCT00700947 ↗ “mortality benefits (carvedilol \[Coreg\] 25 mg bid, metoprolol succinate \[Toprol-XL\] 200 mg qd)” NCT00433043 ↗ “metoprolol succinate (Toprol XL)” NCT01052428 ↗ “Metoprolol- Toprol XL” NCT01523054 ↗ |
| Action | Inhibit | “metoprolol, a conventional β1-selective antagonist” NCT00198614 ↗ |
| Modality | Other / unclassified | “beta blocking agent (metoprolol)” NCT05768542 ↗ |
| Route | Oral | “Metoprolol succinate administered orally” NCT00077948 ↗ |
| Target | ADRB1 | “Its selectivity for ADRB1 over ADRB2 allows it to precisely target the ADRB1 receptor highly expressed on CD8⁺ T cells” NCT07511894 ↗ |